Skip to main content
Portfolio NewsiView Therapeutics

IVIEW Therapeutics Completed A++ Round Financing

By January 17, 2025February 11th, 2025No Comments

IVIEW Therapeutics Completed A++ Round Financing to Advance its innovative Ocular Drug Development Programs

[Cranbury, New Jersey January 17, 2025] IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the successful completion of its A++ round of financing.

 

The funds raised will primarily be used to advance IVIEW’s ocular research and development projects, particularly the clinical development of IVW-1001, a novel TRPM8 agonist targeting improvement of both sign and symptoms for dry eye patients. The project has completed a Phase 1/2 clinical trial across 10 clinical sites in the United States, with topline data expected to be released in the first quarter of 2025. Following the evaluation of clinical data, the company plans to meet with the FDA to determine the next steps for pivotal clinical studies.

Additionally, IVIEW’s IVIEW-1201 project, aimed at the broad-spectrum treatment of acute conjunctivitis, has completed Phase 2 clinical studies. The company has submitted a Phase 3 clinical trial protocol to the U.S. FDA for bacterial conjunctivitis by the end of 2024 and expects to submit a Phase 3 IND application for viral conjunctivitis in 2025. Moreover, the innovative gene therapy project for glaucoma treatment, IVW-2001, based on promising preclinical safety and efficacy data, is anticipated to initiate first-in-human (FIH) clinical trials in the first quarter of 2025.

Dr. Bo Liang, Co-founder, Chairman and CEO of IVIEW Therapeutics, stated, “2024 marks a significant milestone in the development of IVIEW Therapeutics. The successful completion of phase 1/2 clinical trial for IVW-1001 project ahead of schedule has provided us strong confidence to advance to the next stage. Currently, our R&D pipeline covers critical areas in ophthalmology, including dry eye disease, infectious conjunctivitis, myopia, and glaucoma. We are deeply grateful for the recognition and support from both new and existing investors, which further strengthens our commitment to continuously developing innovative drugs and therapies in the field of ophthalmology, breaking through existing treatment bottlenecks, and providing better solutions for patients.”

Ms. Li Jingjie, General Manager of Chongqing Changsheng Shenghe Investment, commented, “Although ophthalmic innovative drugs may not attract as much market attention as oncology drugs, the opportunities in the ophthalmology field are gradually being uncovered and valued. IVIEW’s focus on innovative ophthalmic R&D, with a pipeline targeting major clinical diseases in ophthalmology, positions its products for strong commercial prospects. Dr. Liang Bo, the company’s founder, is not only a professional research scientist with many years experience in ocular drug development but also a successful series entrepreneur, which is one of the reasons we were attracted to invest.”

Mr. Xiaolu Sun, founding partner at Proxima venture, a continuing investor in IVIEW, stated, “The ophthalmic drug market presents significant opportunities. With its visionary innovative product pipeline layout and solid R&D capabilities, IVIEW has the potential to provide global patients with higher-quality and more effective treatment options. Proxima venture will continue to uphold its long-term investment philosophy, fully supporting IVIEW’s future development and aiding its steady progress in the journey of ophthalmic innovation, contributing further to the advancement of novel ophthalmic therapeutics.”

About IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Driven by the pursuit of cutting-edge science, we aim to develop differentiated products that fulfill unmet medical needs. We invest in novel mechanisms of action and advanced drug delivery technology platforms to bring forward assets with potentially superior target product profiles. Our innovative portfolio of small molecules and gene therapy assets covers dry eye, myopia, conjunctivitis, glaucoma, and presbyopia.

Located in Cranbury, New Jersey, IVIEW operates a state-of-the-art 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit our website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com.